As the 6th round of negotiations on the Regional Comprehensive Economic Partnership (RCEP) trade agreement take place in India, people living with HIV are rallying in the streets of New Delhi to warn that harmful intellectual property provisions - put forth by Japan - could severely restrict access to affordable medicines for people in developing countries.
The Australian Medical Association (AMA) wants assurances that a Trans Pacific Partnership (TPP) deal will not push up medicine prices.
Australian Trade Minister Andrew Robb lashed out at consumer groups and the Greens for spreading misinformation about the Trans-Pacific Partnership, before walking into a meeting with 11 trade counterparts in Sydney on Saturday to finalise the "basic elements" of the deal.
Many critics are pointing out that the lack of an Ebola vaccine is due to the intellectual property protections offered through trade deals like the Transatlantic Trade and Investment Partnership.
Social organizations defending the interests of health patients have spoken out against the TPP.
Brand name pharmaceutical companies are advocating for inclusion of disciplines on public pharmaceutical reimbursement programs in the ongoing negotiations of the Trans-Pacific Partnership and the Transatlantic Trade and Investment Partnership.
How the European trade agenda continues to undermine access to medicines
Danish companies — such as pharmaceutical giant Novo-Nordisk, who will get expanded patent protection in Canada — see huge opportunities for boosting their revenues through CETA.
The inclusion of intellectual property in the ongoing negotiations of the Regional Comprehensive Economic Partnership between 16 countries, most of them Asian, is raising concerns about “TRIPS-plus” measures that could jeopardise generic drugs production in India, according to Médecins Sans Frontières.
A leaked copy of the full text of the Canada-EU free trade agreement was posted online late Wednesday and appeared to confirm the fears of the deal’s critics on both sides of the Atlantic.
The Australian Medical Association (AMA) has urged the Australian government to reject provisions in the Trans Pacific Partnership agreement (TPP) that “could undermine the Pharmaceutical Benefits Scheme and compromise the ability of governments to improve public health”.
Peru’s National Association of Pharmaceutical Laboratories (Alafarpe) has filed a petition in the Peruvian courts to stop generic drugs from being sold based on the terms of US-Peru free trade agreement, according to Inca Kola News
The threat of the Transpacific Partnership Agreement to Australia’s Pharmaceutical Benefits Scheme is so real that Michael Moore, CEO of the Public Health Association of Australia, has said “It will cost Australian lives".
UNITAID, a global health initiative has warned against bilateral and regional trade agreements, pushed mostly by Europe and the US, as such agreements go well beyond traditional trade concerns and include provisions that force extensive obligations related to intellectual property and investor protection which would restrict access to medicines.
Ambitious free trade agreements in the Philippines would pose serious threats to access to medicines for the poor by providing greater patent rights to pharmaceutical companies, the EU-ASEAN Campaign Network said Tuesday ahead of an international meeting of pharmaceutical companies in Manila.
A report by the Commons Network and civil society partners shows that the pharmaceutical industry’s wish list for the TTIP is detrimental for public health, will increase the cost of medicines and undermines democratic processes
Le conseiller fédéral suisse Johann Schneider-Ammann a laissé entendre samedi dans la presse alémanique que la question de la protection des brevets pourrait retarder l’accord de libre-échange avec l’Inde.
Nearly two-thirds of Canadians oppose longer patents for brand-name drugs under a proposed trade deal with the European Union, according to a poll commissioned by the Council of Canadians.
Following the public outcry over the EU’s demands for stringent intellectual property rules that would dramatically raise medicines prices in India, you would expect the EU to think twice about making similar demands in future trade agreements. Yet, this is precisely what is going on now in the negotiations for a free trade agreement between the EU and Thailand.
There are apprehensions that TTIP would prevent Indian pharma companies to come to market with the same products - they would need to pass through several rounds of additional tests. As a result, prices will move up significantly.